Klinikum Bremen-Mitte

Running trials

• Not yet recruiting

  Evaluation of iNstroke Aspiration Catheters for Thrombectomy: a Multi-center Prospective Study

  NCT07376447· Source

• Active, not recruiting

  EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

  NCT05029414· Source

• Active, not recruiting

  Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

  NCT04371055· Source

• Active, not recruiting

  Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

  NCT03897127· Phase 3· Source

• Active, not recruiting

  Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

  NCT03647878· Source

• Recruiting

  International HIT-MED Registry (I-HIT-MED)

  NCT02417324· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

  NCT05804032· Phase 3· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab

  NCT03480438· Phase 2· Source

• Completed

  Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL

  NCT01228331· Phase 2/3· Source